Samil, a series of love calls from multinational companies

Even Sandoz products were included

Exclusive distribution and sales contract for all 40 items including the central nervous system

Expected external expansion, etc.

Expanding partners with foreign pharmaceutical companies, proving global standards

Samil Pharmaceutical is receiving a series of love calls from multinational companies.

 

This time, it has decided to exclusively distribute and sell all Sandoz products, including the central nervous system (CNS).

 

The CNS division, which was newly established in 2021, will gain momentum for business expansion.

 

It is evaluated that Samil Pharmaceutical's expansion of partners is because it has met global standards in sales and marketing.

 

Even before Sandoz, the company has partnered with global pharmaceutical companies such as GSK, Abbott, AbbVie, Mundipharma, and Beatrice.

 

It is also affiliated with domestic companies such as Samsung Bioepis.

 

Samil Pharmaceutical exclusively distributes and sells all products, including Sandoz CNS (Central Nervous System).

 

The two companies recently signed such an agreement.

 

Sandoz changed its Korean business to a 100% third-party distribution model.

 

Sandoz is a subsidiary of Novartis in the generic and biosimilar business.

 

Samil Pharmaceutical plans to strengthen the recently expanding CNS field while holding Sandoz products.

 

In order to broaden the CNS lineup in 2021, the company established a new CNS division for sales of the existing neurology team and psychiatric products.

 

In the same year, it signed an exclusive distribution and sales contract for Beatrice's Xanax, Zeldox, and Zoloft in the Korean market.

 

A company official said confidently, "Samil Pharmaceutical will provide the best treatment options for domestic patients by further strengthening its powerful central nervous system disease lineup through the distribution and sales of Sandoz medicines." Sandoz currently has about 40 items in stock.

 

In addition to CNS, it deals with chronic disease products such as Sandoz Amlodipine and Sandos Atorvastatin.

 

This is also exclusively distributed and sold by Samil Pharmaceutical.

 

This is where Samil Pharm's external expansion is expected.

 

The company's sales last year were 179.7 billion won.

 

It is expected to break through 200 billion won this year.

 

Samil Pharmaceutical’s factory in Vietnam

Samil Pharmaceutical is receiving a series of love calls from multinational companies in addition to Sandoz.

 

Prior to Sandoz, it partnered with global pharmaceutical companies such as GSK, Abbott, AbbVie, Mundipharma, and Beatrice.

 

There are also domestic companies such as Samsung Bioepis.

 

It is evaluated that it is because it has met global standards in sales, marketing, and distribution.

 

Sandoz Korea also explained that the decision to partner with Samil Pharmaceutical was made considering △company size, △professionalism in supplying medicines in ophthalmology, liver and stomach, musculoskeletal system, and CNS areas, and long-term collaboration experience and capabilities with many global companies.

 

Samil Pharmaceutical has been making efforts to grow into a global company for several years.

 

△ Established a subsidiary in Vietnam in 2018, △completed the construction of a CDMO plant for eye drops in Vietnam in 2022, △Established a North American subsidiary in Canada in 2022, and △Secured future growth engines by signing contracts for new drug candidates in the global phase 3 clinical trials such as Aramchol and Lorecivivint △ Domestic introduction of excellent foreign medicines, etc.

 

In particular, the Vietnam global eye drop CDMO plant, which had a completion ceremony in November last year, is expected to serve as a stepping stone for global expansion.

 

The factory can produce about 330 million eyedrops per year.

 

It is aiming to obtain GMP approval for DAV in Vietnam and MFDS in Korea by the end of the year at the earliest.

 

Within the next two to three years, the company plans to supply high-quality medicines to the global market through US FDA cGMP, European EMA EU GMP, and Health Canada GMP approvals.